JP7773522B2 - 血漿カリクレイン阻害薬 - Google Patents

血漿カリクレイン阻害薬

Info

Publication number
JP7773522B2
JP7773522B2 JP2023500332A JP2023500332A JP7773522B2 JP 7773522 B2 JP7773522 B2 JP 7773522B2 JP 2023500332 A JP2023500332 A JP 2023500332A JP 2023500332 A JP2023500332 A JP 2023500332A JP 7773522 B2 JP7773522 B2 JP 7773522B2
Authority
JP
Japan
Prior art keywords
mmol
mixture
stirred
chloro
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023500332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533519A (ja
JP2023533519A5 (enExample
Inventor
ヒックス，ジャクリーン・ディー
クアン，ロンゼ
ジンツ，クリストファー・ジェイ
ロンバルド，マシュー・ジェイ
ロペス，ジョーバン・アレクサンダー
マーチャント，ロハン
シャープ，フィリップ・パトリック
ウー，チーカイ
ザオ，チーチャン
チェン，アラン・シー
ヤン，ソン
バオ，ジェンミン
ティアン，マオカン
シェイン－ナンス，ガレン・ポール
Original Assignee
メルク・シャープ・アンド・ドーム・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク・シャープ・アンド・ドーム・エルエルシー filed Critical メルク・シャープ・アンド・ドーム・エルエルシー
Publication of JP2023533519A publication Critical patent/JP2023533519A/ja
Publication of JP2023533519A5 publication Critical patent/JP2023533519A5/ja
Application granted granted Critical
Publication of JP7773522B2 publication Critical patent/JP7773522B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023500332A 2020-07-10 2021-07-06 血漿カリクレイン阻害薬 Active JP7773522B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050220P 2020-07-10 2020-07-10
US63/050,220 2020-07-10
PCT/US2021/040420 WO2022010828A1 (en) 2020-07-10 2021-07-06 Plasma kallikrein inhibitors

Publications (3)

Publication Number Publication Date
JP2023533519A JP2023533519A (ja) 2023-08-03
JP2023533519A5 JP2023533519A5 (enExample) 2024-06-03
JP7773522B2 true JP7773522B2 (ja) 2025-11-19

Family

ID=79552050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023500332A Active JP7773522B2 (ja) 2020-07-10 2021-07-06 血漿カリクレイン阻害薬

Country Status (9)

Country Link
US (1) US12528786B2 (enExample)
EP (1) EP4178620B1 (enExample)
JP (1) JP7773522B2 (enExample)
KR (1) KR20230038526A (enExample)
CN (1) CN116157154B (enExample)
AU (1) AU2021306250A1 (enExample)
CA (1) CA3185597A1 (enExample)
MX (1) MX2023000507A (enExample)
WO (1) WO2022010828A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4210694B1 (en) * 2020-09-10 2025-10-15 Merck Sharp & Dohme LLC Plasma kallikrein inhibitors
WO2024173196A1 (en) * 2023-02-17 2024-08-22 Merck Sharp & Dohme Llc Plasma kallikrein inhibitors
WO2026096331A1 (en) * 2024-10-30 2026-05-07 Merck Sharp & Dohme Llc Plasma kallikrein inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532713A (ja) 2010-08-04 2013-08-19 ノバルティス アーゲー 血漿カリクレイン阻害剤としてのｎ−（（６−アミノ−ピリジン−３−イル）メチル）−ヘテロアリール−カルボキサミド類
JP2018535963A (ja) 2015-10-27 2018-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体
JP2018536648A (ja) 2015-10-27 2018-12-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体
WO2019106375A1 (en) 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Solid forms of a plasma kallikrein inhibitor and salts thereof
JP2023531411A (ja) 2020-06-16 2023-07-24 メルク・シャープ・アンド・ドーム・エルエルシー 血漿カリクレイン阻害剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609866B2 (en) 2009-12-18 2013-12-17 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
HRP20221373T1 (hr) 2014-03-07 2023-01-06 Biocryst Pharmaceuticals, Inc. Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
KR102286305B1 (ko) 2014-07-16 2021-08-09 라이프에스씨아이 파마슈티컬스, 인크. 치료적 억제 화합물
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
WO2017001926A2 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc Therapeutic inhibitory compounds
BR112018008506B8 (pt) 2015-10-29 2023-12-05 Merck Sharp & Dohme Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
EP3612523B1 (en) 2017-04-21 2021-06-09 Boehringer Ingelheim International GmbH Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
CN113039181B (zh) * 2018-08-16 2024-08-13 勃林格殷格翰国际有限公司 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532713A (ja) 2010-08-04 2013-08-19 ノバルティス アーゲー 血漿カリクレイン阻害剤としてのｎ−（（６−アミノ−ピリジン−３−イル）メチル）−ヘテロアリール−カルボキサミド類
JP2018535963A (ja) 2015-10-27 2018-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体
JP2018536648A (ja) 2015-10-27 2018-12-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体
WO2019106375A1 (en) 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Solid forms of a plasma kallikrein inhibitor and salts thereof
JP2023531411A (ja) 2020-06-16 2023-07-24 メルク・シャープ・アンド・ドーム・エルエルシー 血漿カリクレイン阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PUBCHEM[online]，2011年03月29日，Substance Record for SID 116114044，URL<https://pubchem.ncbi.nlm.nih.gov/substance/116114044> ［検索日 2025.04.15］

Also Published As

Publication number Publication date
CN116157154A (zh) 2023-05-23
US12528786B2 (en) 2026-01-20
KR20230038526A (ko) 2023-03-20
WO2022010828A1 (en) 2022-01-13
EP4178620A1 (en) 2023-05-17
CA3185597A1 (en) 2022-01-13
AU2021306250A1 (en) 2023-02-16
EP4178620A4 (en) 2024-08-07
CN116157154B (zh) 2026-05-01
US20230348428A1 (en) 2023-11-02
EP4178620B1 (en) 2026-04-01
JP2023533519A (ja) 2023-08-03
MX2023000507A (es) 2023-02-09

Similar Documents

Publication Publication Date Title
EP3134408B1 (en) FACTOR XIa INHIBITORS
EP3180317B1 (en) FACTOR XIa INHIBITORS
JP7787890B2 (ja) 血漿カリクレイン阻害剤
EP3104702A1 (en) Factor xia inhibitors
EP4178620B1 (en) Plasma kallikrein inhibitors
WO2016018702A1 (en) FACTOR XIa INHIBITORS
KR102931248B1 (ko) 혈장 칼리크레인 억제제
EP4210694A1 (en) Plasma kallikrein inhibitors
JP7794991B2 (ja) 血漿カリクレイン阻害薬
WO2024173196A1 (en) Plasma kallikrein inhibitors
EP4308125B1 (en) Plasma kallikrein inhibitors
RU2849957C1 (ru) Ингибиторы калликреина плазмы
RU2852935C1 (ru) Ингибиторы калликреина плазмы
EP4326274B1 (en) Plasma kallikrein inhibitors
RU2854493C2 (ru) Ингибиторы калликреина плазмы
RU2844952C1 (ru) Ингибиторы калликреина плазмы
WO2026096331A1 (en) Plasma kallikrein inhibitors
HK40094263A (en) Plasma kallikrein inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240524

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251107

R150 Certificate of patent or registration of utility model

Ref document number: 7773522

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150